Regenicin Inc RGIN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.00–0.01
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $767,415.25
- Volume/Avg
- 23,000 / 238,218
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 3
- Website
- https://www.regenicin.com
Valuation
|
Metric
|
RGIN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
RGIN
Financial Strength
|
Metric
|
RGIN
|
|---|---|
Quick Ratio | 0.66 |
Current Ratio | 0.66 |
Interest Coverage | −24.26 |
Quick Ratio
RGIN
Profitability
|
Metric
|
RGIN
|
|---|---|
Return on Assets (Normalized) | −19.66% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RGIN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Khtmgggq | Szfj | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nlwnwyrc | Cktttj | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hwjbngtnl | Lpcsv | $103.7 Bil | |
MRNA
| Moderna Inc | Bppsxqy | Myyq | $47.9 Bil | |
ARGX
| argenx SE ADR | Zpfjsgry | Qbcf | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Hgyclpnp | Ytny | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pqlclwr | Mxbjtbz | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nnpsfdxn | Vzkmkmz | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Byltgsdky | Zlmwbp | $12.8 Bil | |
INCY
| Incyte Corp | Cgtbhwfhz | Gtngzt | $12.1 Bil |